Please try another search
PolyPeptide Group AG operate as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of peptide-based therapies for metabolic disorders, including the GLP-1 receptor agonist drugs for the treatment of type 2 diabetes, obesity, and other co-morbidities, as well as oncology, hormonal disorders, neurology, ophthalmology, cardiovascular, and gastrointestinal applications. It also provides peptides for cosmetics; and individualized peptide therapeutics. The company was founded in 1952 and is headquartered in Baar, Switzerland. PolyPeptide Group AG is a subsidiary of Draupnir Holding B.V.
Name | Age | Since | Title |
---|---|---|---|
Erik H.M. Schropp | 59 | 2021 | Non-Executive Director |
Jane Anne Salik | 70 | 2021 | Non-Executive Director |
Patrick Aebischer | 69 | 2021 | Vice Chairman & Lead Independent Non-Executive Director |
Beat In-Albon | 71 | 2021 | Independent Non-Executive Director |
Philippe A. Weber | 58 | 2021 | Independent Non-Executive Director |
Klaus Peter Wilden | 67 | 2021 | Executive Chair |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review